SCHEMBL22145265

SCHEMBL22145265

O=C(Nc1cc(OCc2ccccc2)c2ccccc2c1-c1ccccc1)c1ccccn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.51
GAA P10253 1/20 0.51
HDAC1 Q13547 3/20 0.49
SGMS2 Q8NHU3 1/20 0.47
KDR P35968 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
KDM4E B2RXH2 2/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
TLR7 Q9NYK1 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
PPIA P62937 1/20 0.43
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22163294 0.93 MAOB (0.49) MAPTGAAHDAC1SGMS2SMN1; SMN2
SCHEMBL22163084 0.90 TLR7 (0.49) MAPTGAAHDAC1TLR7PPIA
SCHEMBL22163295 0.88 SMN1; SMN2 (0.50) MAPTGAAHDAC1SMN1; SMN2KDM4E
SCHEMBL22163296 0.88 MAPT (0.52) MAPTGAASMN1; SMN2KDM4EHTT
SCHEMBL22163287 0.87 PPIA (0.48) MAPTGAAHDAC1SGMS2SMN1; SMN2
SCHEMBL22163293 0.87 MAPT (0.53) MAPTGAAHDAC1SGMS2KDR
SCHEMBL22163288 0.84 GRM4 (0.51) MAPTGAASMN1; SMN2KDM4EKMT2A
SCHEMBL24262933 0.83 MAPT (0.48) MAPTGAAHDAC1SGMS2SMN1; SMN2
SCHEMBL22148988 0.80 PPIA (0.46) MAPTGAASMN1; SMN2KDM4EKMT2A
SCHEMBL22145142 0.78 ALDH1A1 (0.48) MAPTGAAKDRSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898590-B1 METHOD FOR PREPARING INDOLENAPHTHOPYRANS TRANSITIONS OPTICAL LTD (IE) 2023-11-22 EP disclosed
EP-3898636-B9 INDOLONAPHTHOPYRANS TRANSITIONS OPTICAL LTD (IE) 2023-11-08 EP disclosed
EP-3898636-B1 INDOLONAPHTHOPYRANS TRANSITIONS OPTICAL LTD (IE) 2023-08-30 EP disclosed
US-20220073533-A1 Method for Preparing Indolenaphthopyrans TRANSITIONS OPTICAL, LTD. (IE) 2022-03-10 US disclosed
US-20220056039-A1 Indolonaphthopyrans TRANSITIONS OPTICAL, LTD. (IE) 2022-02-24 US disclosed
WO-2020126033-A1 METHOD FOR PREPARING INDOLENAPHTHOPYRANS TRANSITIONS OPTICAL, LTD. (IE) 2020-06-25 WO disclosed
WO-2020126032-A1 INDOLONAPHTHOPYRANS TRANSITIONS OPTICAL, LTD. (IE) 2020-06-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220056039-A1 Indolonaphthopyrans TPH1, TPH2, IDO1 MAPT 1575/4885GAA 4335/4885HDAC1 804/4885
US-20220073533-A1 Method for Preparing Indolenaphthopyrans CCNH, CCNT1, PAH MAPT 2123/4885GAA 2695/4885HDAC1 671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.